Maraviroc 150 Mg Tablet

Maraviroc belongs to a class of medications known as CCR5 antagonists, working through a distinct mechanism compared to many other HIV treatments. Rather than targeting the virus after it has entered a cell, it works by blocking a specific receptor called CCR5 on the surface of certain immune cells, preventing the virus from attaching to and entering these cells in the first place. This unique approach makes it a valuable option for patients whose HIV strain uses the CCR5 receptor to infect cells, as determined through specialized testing before starting treatment. It is used in combination with other antiretroviral medications as part of a comprehensive treatment regimen, particularly for patients who have been treated before and need additional options to help control their infection. Taken orally, typically twice daily, it fits into a structured treatment plan designed by an HIV specialist. Maraviroc offers an important additional tool for patients whose treatment options may be more limited due to prior therapy history or drug resistance. Many patients have achieved meaningful reductions in viral load when this medication is included as part of a personalized combination regimen. Its distinctive entry-blocking mechanism reflects ongoing innovation in HIV research, expanding the range of strategies available to control the virus. Regular monitoring through blood tests helps healthcare providers track treatment response and guide any needed adjustments. With appropriate medical guidance and combination therapy, Maraviroc continues to offer valuable support for patients working to achieve effective, long-term HIV management.